ANAVEX LIFE SCIENCES CORP (AVXL)
Health Care · Clinical-stage CNS biopharmaceuticals / precision medicine · NASDAQ
Anavex is a clinical-stage biotech developing sigma-1 receptor agonists for neurodegenerative and rare CNS disorders, with lead program ANAVEX 2-73 in multiple Alzheimer's and Parkinson's trials.
What ANAVEX LIFE SCIENCES CORP does
Anavex Life Sciences is a clinical-stage biopharmaceutical company developing CNS therapeutics using precision medicine and biomarker identification from genomic data. The company focuses on sigma-1 receptor (SIGMAR1) agonists to treat neurodegenerative diseases (Alzheimer's, Parkinson's), neurodevelopmental disorders (Rett syndrome, Fragile X, schizophrenia), and other rare CNS conditions. Its lead compound, ANAVEX 2-73 (blarcamesine), is in multiple clinical trials across different indications, with ANAVEX 3-71 and several other compounds in various developmental stages.
Themes: ["Alzheimer's disease therapeutics","Parkinson's disease therapeutics","Rare CNS disorders (Rett syndrome, Fragile X)","Neurodegeneration / neuroprotection","Neurodevelopmental disorders","Precision medicine / biomarkers","Sigma-1 receptor modulation"]
Fundamentals
- Price$2.70 as of 2026-07-09 close
- Market cap$248M as of 2026-07-10
- 1-year return-74.9% as of 2026-07-09 close
- ROE-38.8% as of 2026-07-10
- Debt / equity0.00 as of 2026-07-10
- Beta1.15 as of 2026-07-10
Key risks (from latest filing)
["Clinical development risk: Company is clinical-stage with no FDA-approved products; ANAVEX 2-73 is still in multiple clinical trials with no guarantee of success or approval.","Cash burn and financing risk: As a pre-revenue biopharmaceutical, the company requires ongoing capital raises to fund R&D; recent 12-month stock price decline of -74.9% may limit future financing options.","Regulatory and competitive risk: Success depends on FDA approval and differentiation from competitors developing Alzheimer's and Parkinson's therapies; efficacy and safety outcomes in ongoing trials are uncertain."]
Competitors & peers
- Eli Lilly (LLY) — Alzheimer's disease treatments
- Biogen (BIIB) — Alzheimer's and neurodegeneration programs
- Denali Therapeutics (DNLI) — Neurodegeneration / CNS programs
- Sangamo Therapeutics (SGMO) — Gene therapy for rare genetic disorders
- Invitae (NVTA) — Genomic and precision medicine
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.